New strategies in the prevention of restenosis

Critical Care Nursing Quarterly

Volumn 24, Issue 1, 2001, Pages 62-68

  Angerio, Allan D ^a   Fink, Dorothy A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Endothelin 1; ET 1 antagonists; Restenosis; Stents; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIN 1;

CORONARY ARTERY OBSTRUCTION; DRUG ANTAGONISM; HUMAN; METABOLISM; METHODOLOGY; PRIMARY PREVENTION; PROGNOSIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ENDOTHELIUM;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY STENOSIS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; PRIMARY PREVENTION; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; STENTS;

EID: 0035352965     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200105000-00011     Document Type: Article

References (46)

1. Barbiere CC. Percutaneous transluminal coronary angioplasty in high-risk patients. Crit Care Nurse. 1990;10:66-69.
2. Homes LM, Hollabaugh SK. Using the continuous quality improvement process to improve the care of patients after angioplasty. Crit Care Nurse. 1997;17:56-65.
3. Gardner E, Joyce S, Iyer M, Mowery MA, Olson K, Piontek S. Intracoronary stent update: Focus on patient education. Crit Care Nurse. 1996;16:65-75.
4. Miller LA, Briscoe A, Bailey SR, Wright WT, Ebersole DG. Care of the elective intracoronary stent patient. Crit Care Nurse Q. 1996;18:77-91.
5. Pearson S. The heart, part six: Coronary artery disease-2. Nurs Times. 1999;95:42-45.
6. Kastrati A, Schömig A, Dirschinger J, et al. Increased risk of restenosis after placement of gold-coated stents. Results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation. 2000;101:2478-2483.
7. Kirchengast M, Münter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. PSEBM. 1999;221:312-325.
8. Zafar MU, Farkouh ME, Chesebro JH. A practical approach to lower-extremity arterial disease. Patient Care. 2000;34:96-112.
9. Erbel R, Haude M, Hopp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. N Engl J Med. 1998;339:1672-1678.
10. Ross R. The pathogenesis of atherosclerosis. Nature. 1993;362:801-809.
11. Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of a Palmaz-Schatz stents in native coronary arteries: Initial results of a multicenter experience. Circulation. 1992;86:1836-1844.
12. Luscher TF, Wenzel RR, Noll G. Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. Eur Heart J. 1995;16(Suppl C): 59-65.
13. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
14. Luscher TF. Endothelin: systemic arterial and pulmonary effects of a new peptide with potent biological properties. Am Rev Resp Dis. 1992;146(Suppl):S56-S60.
15. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. J Clin Invest. 1990;85:587-590.
16. Masaki T, Vane JR, Vanhoutte PM. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev. 1994;46:137-142.
17. Weissberg PL, Witchell C, Davenport AP, Hesketh TR, Metcalf JC. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S66 are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis. 1990;85:257-262.
18. Shetty SS, Okada T, Webb RL, Del Grande D, Lappe RW. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun. 1993;191:459-464.
19. DeNucci G, Thomas R, D'Orleans-Juste P, et al. Presser effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA. 1988;85:9797-9800.
20. Levin ER. Endothelins. N Engl J Med. 1995;333:356-363.
21. Angerio AD, Kot PA. Closure of the ductus arteriosus -New insights for critical care. Crit Care Nurs Q. 1998;20: 80-85.
22. Angerio AD, Kot PA. Pathophysiology of pulmonary edema. Crit Care Nurs Q. 1994;17:21-26.
23. Angerio AD, Kot PA. High-altitude pulmonary edema: A clinical crisis. Crit Care Nurs Q. 1996;19:70-76.
24. Angerio AD. Endothelin-mediated preeclampsia at high altitude. Crit Care Nurs Q. 2000;23:73-78.
25. Kirchengast M, Münter K. Endothelin and restenosis. Cardiovasc Res. 1998;39:550-555.
26. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
27. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996;271:603-606.
28. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hyperten. 1996;5:35-44.
29. Teplitz L, Siwik DA. Cellular signals in atherosclerosis. J Cardiovasc Nurs. 1994;8:28-52.
30. Bacon CR, Gary NRB, Davenport AP. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res. 1996;79:794-801.
31. Franco-Cereceda A, Grip LG, Moor E, Velander M, Liska J, Lundberg JM. Influence of percutaneous transluminal coronary angioplasty on cardiac release of endothelin, neuropeptide Y and noradrenaline. Int J Cardiol. 1995;48:231-233.
32. Malatino LS, Grassi R, Stancanelli B, et al. Release of immunoreactive endothelin from the heart during percutaneous transluminal angioplasty. Am Heart J. 1993;126:700-702.
33. Ameli S, Kaul S, Castro L, Arora C, Mirea A, Shah PK. Effect of percutaneous transluminal coronary angioplasty on circulating endothelin levels. Am J Cardiol. 1993;72:1352-1356.
34. Kruger D, Giannitsis E, Sheikhzadeh A, Stierle U. Cardiac release and kinetics of endothelin after uncomplicated percutaneous transluminal coronary angioplasty. Am J Cardiol. 1998;81:1421-1426.
35. Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998;98:2108-2116.
36. Ruef J, Hu ZY, Yin L-Y, et al. Induction of vascular endothelial growth factor in balloon-injured baboon arteries: A novel role for reactive oxygen species in atherosclerosis. Circ Res. 1997;81:24-33.
37. Okuda Y, Tsurumaru K, Suzuki S, et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci. 1998;63:477-484.
38. Matsuura A, Yamochi W, Hirata K-I, Kawashima S, Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension. 1998;32:89-95.
39. Goad DL, Rubin J, Wang H, Tashjian AH, Patterson C. Enhanced expression of vascular endothelial growth factor in human SaOS-Z osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor-1. Endocrinology. 1996;137:2262-2268.
40. Li J, Perrella MA, Tsai J-C, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1B in rat aortic smooth muscle cells. J Biol Chem. 1995;270:308-312.
41. Finkenzeller G, Marne D, Weich H, Hug H. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res. 1992;52:4821-4823.
42. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor expression in endothelial cells: Identification of a 5′ enhancer. Circ Res. 1995;77:638-643.
43. A receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs. Cardiovasc Pharmacol. 1997;30:33-41.
44. Dashwood MR, Noertersheuser P, Kirchengast M, Münter K. Altered endothelin-1 binding following balloon angioplasty of pig coronary arteries: Effect of the ETA receptor antagonist, LU 135252. J Cardiovasc Res. 1999;43:445-456.
45. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty: A practical proliferative model in porcine coronary arteries. Circulation. 1990;82:2190-2200.
46. A receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation. 1998;97:2551-2556.